RE: Large trades.2 Oct 2023 13:35
Worth bearing in mind priority review vouchers (if we get) have been sold on for between 60m & 300m.
From memory, i think Novartis paid around the 300m from another company that was awarded it.
Even though we would use it, this must still be classed as an asset not far off the m/c at the moment.